Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown. This is the first prospective study in the field evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based study included a large cohort of PLCH patients followed for a sufficiently long period to address risk factors of long-term outcomes of PLCH patients.
Eligibility criteria
Qualifiers
Age >= 18 years
Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses
Disqualifiers
None
Trial design
Treatments tested in this trial
- Standard of care
Treatment groups
500 Participants
are divided into 1 treatment groupLocations
1French national reference centre for Histiocytoses75010, Paris France
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Source ClinicalTrials.gov